An experimental Alzheimer's drug shows some promise as researchers hunt new approaches
Biogen faces a mixed reception and falling stock prices following the release of data for its experimental tau-targeting Alzheimer's drug.
Velocity timeline
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Biogen has released readout data for an experimental Alzheimer's drug designed to target tau proteins. While some reports describe the results as showing promise, other data has been characterized as disappointing, leading to a slide in Biogen's share price.
Coverage from Bloomberg, Fierce Biotech, and Barron's emphasizes the negative market reaction and the existence of unanswered questions regarding the drug's efficacy. BioPharma Dive and The Boston Globe highlight the drug's potential as researchers continue to seek new approaches to treating the disease.
Future developments depend on how Biogen defends the anti-tau drug and addresses the specific questions raised by the trial data.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
What is the drug's primary target?
The experimental drug is designed to target tau proteins.
How did the market react to the data?
Biogen shares fell following the release of the Alzheimer's tau trial data.
What is the general consensus on the trial results?
The results are mixed, with some coverage noting promise while other reports highlight unanswered questions and disappointing data.
Coverage (5)
- Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs BioPharma Dive · 8h ago
- An experimental Alzheimer’s drug shows some promise as researchers hunt new approaches The Boston Globe · 8h ago
- Biogen’s Alzheimer’s Drug Leaves Questions Unanswered, and That’s a Problem Barron's · 8h ago
- Biogen defends anti-tau drug after stock slides on Alzheimer’s readout Fierce Biotech · 8h ago
- Biogen Shares Fall as Alzheimer’s Tau Trial Data Disappoint Bloomberg.com · 8h ago broke it first
People, places & organizations
Topics
From around our network
Related trends
All eyes on data on Biogen’s tau therapy
Biogen's experimental anti-tau therapy shows promise in slowing cognitive decline for early Alzheimer's patients.
Agitation in Dementia Can Be Helped by Medical Cannabis, Study Suggests
A new study suggests medical cannabis can reduce agitation and confusion in patients with late-stage dementia.
Can 2 drugs work better than 1 against Alzheimer’s? UCSF aims to find out
UCSF has begun screening patients for a novel trial testing whether a combination of two drugs is more effective against Alzheimer's than a single treatment.
An anti-inflammatory diet may protect against dementia in some older adults
Recent findings suggest that adopting an anti-inflammatory diet and healthy behaviors may significantly reduce dementia risk for some older adults.
Early-Onset Alzheimer’s: The Symptoms Beyond Memory Loss
Emerging research highlights non-memory symptoms and early detection methods as key priorities in the study of Alzheimer's disease.
Learning What Substance Is Suspected of Causing Alzheimer's May Throw You Into an Existential Crisis
A new study suggests a common chemical found in car tire wear pollution may be linked to an increased risk of Alzheimer's and dementia.